VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Abobotulinum toxin A
Preclinical
Small molecule
F
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
1
Indications
4
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Tourette's Syndrome
Unknown status
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Tourette's Syndrome
Preclinical
Unknown status
Clinical
Trials by Indication
[1]
Tremor
1 trial
A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor
Recruiting
·
—
·
Phase 4
·
NCT03136341
·
25 enrolled
Tourette's Syndrome
1 trial
Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome
Unknown status
·
—
·
N/A
·
NCT02187679
·
30 enrolled
Botulinum Toxin
1 trial
Frontalis Botulinum Toxin
Unknown status
·
S
St Joseph University, Beirut, Lebanon
·
Phase 4
·
NCT03186001
·
30 enrolled
Mobility
1 trial
Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)
Unknown status
·
F
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
·
·
NCT05151874
·
12 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
4 trial records for Abobotulinum toxin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Abobotulinum toxin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Abobotulinum toxin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
F
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Related News